Peters et al. [31] evaluated surveillance strategies of MRI (one time, every 5 years, every 2 years, and annually) with follow-up EUS for eight separate high risk groups (BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11) and varied their starting ages (40–70 years old). The gene discussed is PALB2; the disease is Lynch syndrome.